Citius Oncology, Inc. (CTOR) — Cash Flow Quality Index
Latest as of June 2024:
-1.44x
Citius Oncology, Inc. (CTOR) has a Cash Flow Quality Index of -1.44x as of June 2024. Operating cash flow of $-364.06K is below net income of $252.46K, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Citius Oncology, Inc. to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
-1.44x
Operating CF / Net Income
Operating Cash Flow
$-364.06K
USD
Net Income
$252.46K
USD
Data as of
Jun 2024
Most recent filing
Citius Oncology, Inc. Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Citius Oncology, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see CTOR cash flow conversion.
Annual Cash Flow Quality Index for Citius Oncology, Inc. (2022–2023)
Year-by-year earnings quality comparison for Citius Oncology, Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | -0.25x | $-601.30K | $2.42 Million | ▼ -97.3% |
| 2022 | -0.13x | $-47.97K | $380.81K | — |
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.